US Patent

US8648097 — Pyridylaminoacetic acid compound

Composition of Matter · Assigned to Ube Industries Ltd · Expires 2029-10-13 · 3y remaining

Vulnerability score 18/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects a novel pyridylaminoacetic acid compound, or a pharmacologically acceptable salt thereof, with EP2 agonistic action.

USPTO Abstract

The present invention provides a novel pyridylaminoacetic acid compound represented by the following formula (1): (wherein R1, R2, R3, Y and Z are as defined in the description and claims), or a pharmacologically acceptable salt thereof. The pyridylaminoacetic acid compound has EP2 agonistic action and is therefore useful as a therapeutic and/or prophylactic agent for respiratory diseases such as asthma or chronic obstructive pulmonary disease.

Drugs covered by this patent

Patent Metadata

Patent number
US8648097
Jurisdiction
US
Classification
Composition of Matter
Expires
2029-10-13
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Ube Industries Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.